Biocon Limited

NSEI:BIOCON Stok Raporu

Piyasa değeri: ₹697.3b

Biocon Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Biocon kazanç ve gelirin sırasıyla yıllık 47.6% ve 13.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 44.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 5.7% olacağı tahmin edilmektedir.

Anahtar bilgiler

47.6%

Kazanç büyüme oranı

44.49%

EPS büyüme oranı

Biotechs kazanç büyümesi35.2%
Gelir büyüme oranı13.1%
Gelecekteki özkaynak getirisi5.68%
Analist kapsamı

Good

Son güncelleme21 May 2026

Gelecekteki son büyüme güncellemeleri

Analiz Makalesi • Aug 10

Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models

NSEI:BIOCON 1 Year Share Price vs Fair Value Explore Biocon's Fair Values from the Community and select yours There's...
Analiz Makalesi • Jun 19

Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next

Shareholders might have noticed that Biocon Limited ( NSE:BIOCON ) filed its yearly result this time last week. The...

Recent updates

Analiz Makalesi • May 21

Biocon's (NSE:BIOCON) Weak Earnings May Only Reveal A Part Of The Whole Picture

The subdued market reaction suggests that Biocon Limited's ( NSE:BIOCON ) recent earnings didn't contain any surprises...
Anlatı Güncellemesi • May 03

BIOCON: Leadership Changes And Biosimilars Expansion Will Support Future Upside

Biocon's analyst price target has been trimmed slightly to about ₹416 from roughly ₹421 as analysts factor in a marginally higher discount rate, slightly softer revenue growth and profit margin assumptions, partly balanced by a modestly higher future P/E multiple. Analyst Commentary Recent Street research around comparable life sciences names points to a cautious tone on execution risk, revenue trajectory and the willingness of the market to pay up for growth after guidance disappointments.
Anlatı Güncellemesi • Apr 19

BIOCON: Higher Profitability Assumptions Will Support U.S. Biosimilars And GLP-1 Entry

Narrative Update on Biocon Analysts have adjusted their price target on Biocon to ₹544, up from ₹465. This reflects updated assumptions around a higher fair value estimate, revised profit margin expectations, and a slightly different discount rate and forward P/E framework.
Anlatı Güncellemesi • Apr 05

BIOCON: Leadership Refresh And Biosimilars Integration Will Support Future Upside

Analysts have trimmed Biocon's fair value estimate slightly to ₹420.74 from ₹421.60, reflecting updated assumptions around the discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Analysts are treating the trimmed fair value estimate as a fine tuning of expectations rather than a major reset, with views split between what could support upside and what might cap near term returns.
Anlatı Güncellemesi • Mar 21

BIOCON: Limited P/E Expansion Will Constrain Returns Despite New Metabolic Drug Approvals

Analysts have trimmed their Biocon price target slightly to about ₹295.70 from roughly ₹297.40, reflecting a modest recalibration of fair value, discount rate and long term assumptions for revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts trimming Biocon's fair value signal a more careful stance on what they are willing to pay for the shares today, given reassessed views on growth, profitability and valuation multiples.
Anlatı Güncellemesi • Mar 07

BIOCON: Limited Multiple Expansion Will Constrain Returns Despite New GLP 1 Approvals

Narrative update Analysts have trimmed their Biocon price target slightly to about ₹297 from roughly ₹298, reflecting updated assumptions on discount rate, revenue growth, profit margins and future P/E multiples after recent sector research signalled a more cautious stance on multiple expansion. Analyst Commentary Bearish analysts looking at global life sciences peers have trimmed price targets after recent earnings misses and cautious forward commentary, and those moves are informing how some investors think about Biocon's risk and valuation setup.
Anlatı Güncellemesi • Feb 21

BIOCON: Execution And Multiple Compression Risks Will Restrain Future Share Returns

Analysts have inched up their Biocon fair value estimate to about ₹298 per share from roughly ₹295, reflecting slightly lower discount rate assumptions, modestly softer revenue growth expectations, a somewhat stronger profit margin outlook, and a marginally reduced future P/E multiple. Analyst Commentary While the fair value adjustment for Biocon is modest, some bearish analysts are still flagging risks that could cap upside in the near term.
Anlatı Güncellemesi • Feb 07

BIOCON: Equity Dilution And Biosimilars Review Will Pressure Future Returns

Analysts have slightly reduced their Biocon fair value estimate to ₹295.12 from ₹296.78, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News Biocon completed a follow on equity offering of equity shares worth ₹41.5b, issuing 112,664,585 common shares at ₹368.35 each under a Regulation S structure with a subsequent direct listing (company filing).
Anlatı Güncellemesi • Jan 23

BIOCON: Biosimilars Reorganisation And GLP 1 Expansion Will Drive Future Upside

Analysts have nudged their fair value estimate for Biocon higher from ₹412.05 to ₹421.60, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples in their valuation work. What's in the News Biocon completed a follow on equity offering of ₹41.5b, issuing 112,664,585 equity shares at ₹368.35 per share under Regulation S, followed by a subsequent direct listing (Key Developments).
Anlatı Güncellemesi • Jan 09

BIOCON: Planned Capital Raise Will Likely Weigh On Future Shareholder Returns

Analysts have lifted their price target on Biocon from ₹290.00 to about ₹296.78, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and forward P/E inputs in their models. What's in the News Shareholders approved amendments to Biocon's Articles of Association at the AGM held on December 31, 2025, signaling changes to the company's governing documents (Key Developments).
Anlatı Güncellemesi • Dec 26

BIOCON: Future Equity Issuance Will Likely Pressure Shareholder Returns

Analysts have maintained their fair value estimate for Biocon at ₹290.00 per share, with only minor model adjustments to discount rate, revenue growth, and profit margin assumptions. These changes have resulted in no alteration to their overall price target, as they continue to view the company’s long term earnings profile as broadly intact.
Analiz Makalesi • Dec 25

Calculating The Fair Value Of Biocon Limited (NSE:BIOCON)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Biocon fair value estimate is ₹364 With ₹398 share price...
Anlatı Güncellemesi • Dec 12

BIOCON: Future Share Dilution Risk Will Likely Pressure Returns

Analysts have raised their price target on Biocon from ₹277.50 to ₹290.00, reflecting higher anticipated revenue growth, improved profit margins, and a modestly re-rated future P E multiple despite a slightly higher discount rate. What's in the News Biocon is exploring strategic options for its biosimilars arm Biocon Biologics Limited, including a potential merger with the parent company in place of an IPO, with Morgan Stanley advising on value creation alternatives (Key Developments).
Analiz Makalesi • Dec 07

Investors Don't See Light At End Of Biocon Limited's (NSE:BIOCON) Tunnel

You may think that with a price-to-sales (or "P/S") ratio of 3.2x Biocon Limited ( NSE:BIOCON ) is a stock worth...
Anlatı Güncellemesi • Nov 27

BIOCON: Global Expansion And Business Restructuring Are Expected To Balance Opportunities And Risks

Analysts have raised their price target for Biocon from ₹395.65 to ₹412.05. This change reflects updated expectations around key valuation inputs and profitability metrics.
Analiz Makalesi • Nov 19

Weak Statutory Earnings May Not Tell The Whole Story For Biocon (NSE:BIOCON)

The market rallied behind Biocon Limited's ( NSE:BIOCON ) stock, leading do a rise in the share price after its recent...
Anlatı Güncellemesi • Nov 13

BIOCON: Revenue Outlook And Global Expansion Likely To Support Steady Performance

Analysts have raised Biocon's fair value price target from ₹376.70 to ₹395.65, citing improved revenue growth projections and profit margins as key drivers for the upgrade. What's in the News Biocon announced the public funding of YESAFILI (aflibercept), a biosimilar to EYLEA, on the Ontario Drug Benefit Formulary in Canada for retinal disease treatment.
Anlatı Güncellemesi • Oct 05

Biosimilars Demand Will Unlock Global Market Opportunities

Analysts have lowered Biocon's price target slightly from ₹380.11 to ₹376.70, citing marginal adjustments in the discount rate and projected earnings metrics. Analyst Commentary Market watchers have weighed in on Biocon's valuation following the recent adjustment to its price target.
Analiz Makalesi • Sep 22

Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 56% Above Its Share Price

Key Insights The projected fair value for Biocon is ₹577 based on 2 Stage Free Cash Flow to Equity Biocon's ₹369 share...
Analiz Makalesi • Aug 10

Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models

NSEI:BIOCON 1 Year Share Price vs Fair Value Explore Biocon's Fair Values from the Community and select yours There's...
Analiz Makalesi • Aug 04

Pinning Down Biocon Limited's (NSE:BIOCON) P/E Is Difficult Right Now

Biocon Limited's ( NSE:BIOCON ) price-to-earnings (or "P/E") ratio of 50.5x might make it look like a strong sell right...
Analiz Makalesi • Jun 19

Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next

Shareholders might have noticed that Biocon Limited ( NSE:BIOCON ) filed its yearly result this time last week. The...
Analiz Makalesi • Jun 18

Biocon (NSE:BIOCON) Will Pay A Dividend Of ₹0.50

The board of Biocon Limited ( NSE:BIOCON ) has announced that it will pay a dividend on the 5th of September, with...
User avatar
Yeni Anlatı • Dec 12

Tactical Biosimilars Expansion And Viatris Integration Will Propel Revenue Growth And Boost Profitability

Strategic cost improvements and production efficiencies are set to enhance margins and profitability in the generics segment.

Kazanç ve Gelir Büyüme Tahminleri

NSEI:BIOCON - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
3/31/2029249,13321,93924,82747,1416
3/31/2028228,62819,94527,42741,52218
3/31/2027200,53413,69222,77538,09618
3/31/2026169,2703,85682319,940N/A
12/31/2025168,2746,042N/AN/AN/A
9/30/2025164,7584,85517,97341,592N/A
6/30/2025157,7073,850N/AN/AN/A
3/31/2025152,61710,13317,17940,612N/A
12/31/2024147,6188,043N/AN/AN/A
9/30/2024148,94114,39221,04540,368N/A
6/30/2024147,66015,808N/AN/AN/A
3/31/2024147,55710,22510,22329,539N/A
12/31/2023146,12512,002N/AN/AN/A
9/30/2023135,9994,984-6,24111,717N/A
6/30/2023124,5734,197N/AN/AN/A
3/31/2023111,7424,6271,26218,525N/A
12/31/202298,0913,881N/AN/AN/A
9/30/202290,4226,170-6,83611,543N/A
6/30/202285,6297,084N/AN/AN/A
3/31/202281,8406,484-7,48211,766N/A
12/31/202175,8006,727N/AN/AN/A
9/30/202172,6326,542-6,36612,763N/A
6/30/202171,7266,852N/AN/AN/A
3/31/202171,4317,405-5,86611,597N/A
12/31/202068,9135,996N/AN/AN/A
9/30/202067,5716,362-6,57610,484N/A
6/30/202065,7966,870N/AN/AN/A
3/31/202063,0057,771-5,53412,831N/A
12/31/201963,1508,385N/AN/AN/A
9/30/201961,0778,529N/A14,573N/A
6/30/201958,5659,919N/AN/AN/A
3/31/201955,1449,053N/A11,546N/A
12/31/201851,5518,220N/AN/AN/A
9/30/201846,7226,967N/AN/AN/A
6/30/201843,1984,108N/AN/AN/A
3/31/201841,2343,724N/A6,621N/A
12/31/201738,7923,695N/AN/AN/A
9/30/201738,5894,489N/AN/AN/A
6/30/201738,3615,268N/AN/AN/A
3/31/201738,9116,121N/A6,400N/A
12/31/201640,48711,633N/AN/AN/A
9/30/201638,11010,961N/AN/AN/A
6/30/201636,5399,388N/AN/AN/A
3/31/201633,4745,504N/A3,706N/A
12/31/201532,9977,367N/AN/AN/A
9/30/201532,3257,247N/AN/AN/A
6/30/201531,5285,207N/AN/AN/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: BIOCON 'nin tahmini kazanç büyümesi (yıllık 47.6% ) tasarruf oranının ( 6.9% ) üzerindedir.

Kazançlar ve Piyasa: BIOCON şirketinin kazançlarının (yıllık 47.6% ) Indian pazarından (yıllık 16.3% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: BIOCON şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: BIOCON şirketinin gelirinin (yıllık 13.1% ) Indian pazarından (yıllık 10.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: BIOCON şirketinin gelirinin (yıllık 13.1% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: BIOCON 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 5.7 %).

Büyüyen şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/21 07:49
Gün Sonu Hisse Fiyatı2026/05/21 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2026/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Biocon Limited 39 Bu analistlerden 18, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Rohit Bhat360 ONE Capital Market Private Limited
Meeta ShettyAsian Markets Securities Private Limited
Harith AhamedAvendus Spark